Vector Development Core

 

     The Vaccine Technology/Vector Core will greatly facilitate co-operative LVC/SLIIDR research through the design, engineering, preparation and purification of new recombinant vaccine vectors and novel vector technology. The Vector Core is based at LSUHSC in the Gene Therapy Program.

     Core services include construction of new recombinant vectors, and large-scale preparation of recombinant vectors for use, quality control. The Core maintains an extensive inventory of plasmids and cell lines that are useful in the development of recombinant vectors.

     Several vaccine vector systems are currently available through the Core: DNA vaccines, replication-defective adenoviral vectors, lentiviral vectors, and vectors based on oncogenic retroviruses including mouse stem cells virus (MSCV). More recent additions include vectors based on poxviruses (vaccinia or fowlpox) and adeno-associated virus (AAV). Current serotypes of the latter include AAV1, 2, 5, 7, 8, 9 and AAVrh10.

     The Core is already equipped for manufacture of the above mentioned vector systems through LSUHSC, Gene Therapy Consortium and NIH funding.

 

Location:

LSU Health Sciences Center